Dr. Amy Reichelt

Chief Innovation Officer at Purminds Neuropharma

Dr Reichelt is Chief Innovation Officer at Purminds Neuropharma, where she is responsible for directing and developing clinical and preclinical elements of multiple drug development pipelines for neurological disorders, spanning classic psychedelics, non-hallucinogenic new chemical entities and botanical drugs. She is also Adjunct Faculty at University of Adelaide, and serves as on the board of directors in Women in Psychedelics Network. Dr Reichelt has experience in the management of first in human clinical trials with psychedelic drugs for mood and anxiety disorders. Dr Reichelt has a PhD in Neuroscience from Cardiff University, and directed academic research programs in neuroplasticity and cognitive impairment as a Principal Investigator at UNSW Sydney and RMIT University Melbourne.